title: Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy.
abstract: Candida is an important cause of bloodstream infections (BSI), causing significant mortality and morbidity in health care settings. From January 2008 to December 2010 all consecutive patients who developed candidemia at San Martino University Hospital, Italy were enrolled in the study. A total of 348 episodes of candidaemia were identified during the study period (January 2008-December 2010), with an incidence of 1,73 episodes/1000 admissions. Globally, albicans and non-albicans species caused around 50% of the cases each. Non-albicans included Candida parapsilosis (28.4%), Candida glabrata (9.5%), Candida tropicalis (6.6%), and Candida krusei (2.6%). Out of 324 evaluable patients, 141 (43.5%) died within 30 days from the onset of candidemia. C. parapsilosis candidemia was associated with the lowest mortality rate (36.2%). In contrast, patients with C. krusei BSI had the highest mortality rate (55.5%) in this cohort. Regarding the crude mortality in the different units, patients in Internal Medicine wards had the highest mortality rate (54.1%), followed by patients in ICU and Hemato-Oncology wards (47.6%).This report shows that candidemia is a significant source of morbidity in Italy, with a substantial burden of disease, mortality, and likely high associated costs. Although our high rates of candidemia may be related to high rates of BSI in general in Italian public hospitals, reasons for these high rates are not clear and warrant further study. Determining factors associated with these high rates may lead to identifying measures that can help to prevent disease.
authors.affiliation: Infectious Diseases Division, Santa Maria Misericordia University Hospital, Udine, Italy. mattba@tin.it
authors.forename: Matteo
authors.initials: M
authors.lastname: Bassetti
authors.forename: Lucia
authors.initials: L
authors.lastname: Taramasso
authors.forename: Elena
authors.initials: E
authors.lastname: Nicco
authors.forename: Maria Pia
authors.initials: MP
authors.lastname: Molinari
authors.forename: Michele
authors.initials: M
authors.lastname: Mussap
authors.forename: Claudio
authors.initials: C
authors.lastname: Viscoli
mesh_terms: D000368:Aged; D000666:Amphotericin B / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology*; D002177:Candidiasis / Q000188:drug therapy* / Q000453:epidemiology; D000077336:Caspofungin; D003140:Communicable Disease Control / Q000379:methods; D003428:Cross Infection / Q000188:drug therapy* / Q000453:epidemiology; D054714:Echinocandins / Q000494:pharmacology; D005260:Female; D015725:Fluconazole / Q000494:pharmacology; D006761:Hospitals; D006801:Humans; D007558:Italy; D017964:Itraconazole / Q000494:pharmacology; D055666:Lipopeptides; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000494:pharmacology; D016896:Treatment Outcome; D014230:Triazoles / Q000494:pharmacology; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D011743:Pyrimidines; D014230:Triazoles; D017964:Itraconazole; D000666:Amphotericin B; D015725:Fluconazole; D000077336:Caspofungin; D065819:Voriconazole